Flora Growth Corp. (NASDAQ:FLGC – Free Report) – Stock analysts at Roth Capital dropped their Q2 2025 earnings per share (EPS) estimates for Flora Growth in a research report issued on Friday, November 15th. Roth Capital analyst W. Kirk now anticipates that the company will post earnings per share of $0.02 for the quarter, down from their prior estimate of $0.07. The consensus estimate for Flora Growth’s current full-year earnings is ($0.48) per share. Roth Capital also issued estimates for Flora Growth’s Q3 2025 earnings at $0.02 EPS and Q4 2025 earnings at $0.02 EPS.
Separately, Alliance Global Partners reaffirmed a “neutral” rating on shares of Flora Growth in a research note on Thursday, August 15th.
Flora Growth Trading Down 10.7 %
Flora Growth stock opened at $1.17 on Monday. Flora Growth has a one year low of $0.70 and a one year high of $2.93. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.02 and a quick ratio of 0.79. The business has a fifty day moving average of $1.46 and a two-hundred day moving average of $1.23.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Flora Growth stock. XTX Topco Ltd purchased a new position in shares of Flora Growth Corp. (NASDAQ:FLGC – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 18,070 shares of the company’s stock, valued at approximately $28,000. XTX Topco Ltd owned about 0.14% of Flora Growth as of its most recent SEC filing. Institutional investors own 36.01% of the company’s stock.
About Flora Growth
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.
Featured Stories
- Five stocks we like better than Flora Growth
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- What Are Growth Stocks and Investing in Them
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Insider Trading – What You Need to Know
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Flora Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flora Growth and related companies with MarketBeat.com's FREE daily email newsletter.
